2Xideas AG Acquires 25,887 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

2Xideas AG lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 29.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 113,781 shares of the medical device company’s stock after purchasing an additional 25,887 shares during the period. 2Xideas AG owned 0.06% of Cooper Companies worth $10,460,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COO. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Cooper Companies in the 4th quarter worth approximately $691,000. Highland Capital Management LLC bought a new stake in shares of Cooper Companies during the fourth quarter worth $4,004,000. Caprock Group LLC acquired a new position in shares of Cooper Companies during the fourth quarter valued at $282,000. Franklin Resources Inc. boosted its holdings in Cooper Companies by 194.0% in the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after acquiring an additional 32,260 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Cooper Companies by 6.6% in the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock worth $26,295,000 after purchasing an additional 14,687 shares during the period. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on COO shares. Citigroup cut their target price on shares of Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research report on Friday, March 7th. BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Needham & Company LLC reiterated a “hold” rating on shares of Cooper Companies in a research report on Friday, March 7th. Piper Sandler reissued an “overweight” rating and issued a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Finally, JPMorgan Chase & Co. decreased their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $110.25.

Cooper Companies Stock Down 5.6 %

Shares of Cooper Companies stock opened at $73.77 on Friday. The company has a market capitalization of $14.75 billion, a P/E ratio of 37.83, a price-to-earnings-growth ratio of 2.25 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12. The business has a 50-day moving average of $87.76 and a two-hundred day moving average of $96.24. The Cooper Companies, Inc. has a 1 year low of $73.34 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current year.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.